Zenas BioPharma (NASDAQ: ZBIO) net income
Zenas BioPharma reported a net loss of $377.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $157.0m. Earnings per share were −$8.44.
Zenas BioPharma's best year of the last 3 was fiscal 2023. It reported a loss in 3 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$377.7m | — | −3,777.4% | −$8.44 |
| 2024 | −$157.0m | — | −3,139.8% | −$11.89 |
| 2023 | −$37.1m | — | −74.2% | −$24.25 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Zenas BioPharma net income compared with its sector
By net income for its latest fiscal year, Zenas BioPharma ranks 461st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Zenas BioPharma, −3,777.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 459th | Bausch & Lomb | −$360.0m | −7.1% |
| 460th | Myriad Genetics | −$365.9m | −44.4% |
| 461st | Zenas BioPharma | −$377.7m | −3,777.4% |
| 462nd | Scholar Rock | −$377.9m | — |
| 463rd | Ionis Pharmaceuticals | −$381.4m | −40.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Zenas BioPharma
- How much did Zenas BioPharma earn in fiscal 2025?
- Zenas BioPharma reported a net loss of $377.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $157.0m.
- What are the earnings per share of Zenas BioPharma?
- They were −$8.44 in fiscal 2025, compared with −$11.89 in fiscal 2024.
- Where does Zenas BioPharma rank in its sector by net income?
- It ranks 461st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Zenas BioPharma come from?
- From the annual report (Form 10-K) that Zenas BioPharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Zenas BioPharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Zenas BioPharma: the Zenas BioPharma page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.